The research is designed to test rapcabtagene autoleucel (administered once following lymphodepletion) versus Standard of Care (SOC) in patients with systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN). The primary purpose of this study is to evaluate the safety and efficacy of rapcabtagene autoleucel by measuring the Percentage of participants achieving remission after 1 year.
Sponsor
Novartis Pharmaceuticals
Status of enrollment
Accepting new patients
Ages Eligible for Study
Adults aged 18-65 years
Genders Eligible for Study
Female and Male
Disease indication
Systemic Lupus Erythematosus (SLE) with Lupus Nephritis (LN)
Principal Investigator
Emily Von Scheven MD
Contact
Zilan Zheng
Additional study eligibility details can be found at UCSF Clinical Trials.